Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention.
Enrico FabrisJan Paul OttervangerRenicus S HermanidesJurrien M Ten BergGianfranco SinagraPetra C KoopmansEvangelos GiannitsisChristian HammArnoud W J van 't HofPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
In a large cohort of STEMI patients, pre-hospital tirofiban administration was independently associate with a lower risk of high NT-proBNP level after primary PCI, supporting the potential benefit of early antithrombotic treatment administration in STEMI patients. The trial is registered under No. ISRCTN06195297.
Keyphrases
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- st segment elevation myocardial infarction
- chronic kidney disease
- st elevation myocardial infarction
- newly diagnosed
- healthcare
- atrial fibrillation
- clinical trial
- randomized controlled trial
- prognostic factors
- coronary artery bypass grafting
- study protocol
- emergency department
- climate change
- adverse drug
- left ventricular